Here are five things to know about Pacira’s financial report:
1. The total fourth quarter net revenues hit $69.3 million, up over the $61.8 million reported for the fourth quarter last year. Full year company revenues increased from $197.7 million in 2014 to $249 million in 2015.
2. Exparel net product revenue reached $239.9 million in 2015, up significantly from $188.5 million in 2014. Fourth quarter Exparel net product revenue grew from $61.8 million in 2014 to $69.3 million in 2015.
3. Total operating expenses for the full year were $239.5 million and net income was $1.9 million; fourth quarter operating expenses reached $70.1 million net loss was $2.5 million.
4. Pacira ended the year with $172.4 million in cash and cash equivalents, short-term investments and long-term investments. The company has 26.5 million basic and 41.3 million diluted weighted average shares of common stock outstanding for the 2015 fiscal year.
5. The company expects research and development to hit $60 million to $70 million in 2016. Selling, general and administrative expenses are expected to be $125 million to $135 million. Stock-based compensation expense is expected at $35 million to $40 million.
More articles on orthopedic devices:
Globus Medical 2015 net income hits $112.8M: 6 things to know
Global orthopedic devices market to grow at CAGR of 4%: 5 notes
European spine surgery devices to reach $3B—3 takeaways
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
